A study to evaulate the most favourable treatment dose in childrens and adolescents with Attention-Deficit Hyperactivity Disorder - Trial 2015-001218-92
Access comprehensive clinical trial information for 2015-001218-92 through Pure Global AI's free database. This phase not specified trial is sponsored by Janssen Korea Ltd and is currently status unknown. The study focuses on Attention Deficit Hyperactivity Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2015-001218-92
Trial Details
EU Clinical Trials Register • 2015-001218-92
A study to evaulate the most favourable treatment dose in childrens and adolescents with Attention-Deficit Hyperactivity Disorder
Study Focus
Sponsor & Location
Janssen Korea Ltd
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
- Subject who was administered with Methylphenidate HCl besides Concerta® within 24 hrs of study participation
ICD-10 Classifications
Neurotic disorder, unspecified
Hyperkinetic disorder, unspecified
Hyperkinetic disorders
Disorder of brain, unspecified
Hyperkinetic conduct disorder
Data Source
EU Clinical Trials Register
2015-001218-92
Non-Device Trial